Invivo anti-human CD32 (FcγRIIA) Recombinant mAb

產(chǎn)品型號：S0B0689

更新時間：2025-07-01

廠商性質(zhì)：生產(chǎn)廠家

訪問量：34

服務(wù)熱線

15855403091

立即咨詢

產(chǎn)品分類

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標(biāo)簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對抗體病理/IHC抗體

查看全部產(chǎn)品

相關(guān)文章

腫瘤靶點(diǎn)的“新寵”-Claudin18.2抗體現(xiàn)貨！

基因治療中重要的AAV抗體

CDx 抗體 | 新興靶點(diǎn)B7-H3/H4，助力ADC藥物研發(fā)

DT3C賦能ADC藥物研發(fā)：高效檢測抗體內(nèi)化效率

產(chǎn)品介紹

FcγRIIA is a specific receptor for immunoglobulin G （IgG）, belonging to the family of Fcγ receptors （FcγR）. Among the FcγRs, FcγRIIA functions as an activating receptor. This receptor is primarily expressed on the membranes of immune cells, such as human platelets, and serves as a bridge between specific antibodies and effector cell functions, tightly linking humoral immunity with cellular immunity. FcγRIIA plays a crucial role in regulating IgG effects, as it can bind to monomeric and immune complex （IC） IgG. It can induce either activation or inhibition of functions, participating in driving antibody effector functions such as antibody-dependent cell-mediated cytotoxicity （ADCC） and/or antibody-dependent cellular phagocytosis （ADCP）, as well as antigen presentation and the release of chemokines and cytokines. In autoimmune inflammatory diseases like systemic lupus erythematosus （SLE）, the expression of FcγRIIA may exacerbate lupus nephritis and promote platelet activation.

上一個：S0B0690Invivo anti-mouse CD4 Recombinant mAb